New Zealand vs South-East Asia (WHO region): Treatment success rate for patients treated for MDR-TB
New Zealand
100.0%
in 2022
South-East Asia (WHO region)
77.0%
in 2022
New Zealand rank
1st
South-East Asia (WHO region) rank
2nd
Treatment success rate for patients treated for MDR-TB over time
- New Zealand
- South-East Asia (WHO region)
How they compare
New Zealand currently reports 100.0% against 77.0% in South-East Asia (WHO region), a difference of 23.0%.
That makes New Zealand's figure about 1.3 times South-East Asia (WHO region)'s.
The two have swapped places 5 times across 15 shared years of data; in 2007 it was South-East Asia (WHO region) ahead.
New Zealand ranks 1st and South-East Asia (WHO region) ranks 2nd of 163 countries.
Across the 3 decades both report, New Zealand averaged higher in 2 and South-East Asia (WHO region) in 1.
Head to head by decade
| Decade | New Zealand | South-East Asia (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 46.5% | 62.5% | 16.0% | South-East Asia (WHO region) |
| 2010s | 66.6% | 52.7% | 13.9% | New Zealand |
| 2020s | 100.0% | 73.0% | 27.0% | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, New Zealand or South-East Asia (WHO region)?
- New Zealand, at 100.0% against 77.0% in South-East Asia (WHO region) as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between New Zealand and South-East Asia (WHO region)?
- 23.0%, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and South-East Asia (WHO region)?
- 15 years are reported by both, from 2007 to 2022.
- How do New Zealand and South-East Asia (WHO region) rank globally for treatment success rate for patients treated for mdr-tb?
- New Zealand ranks 1st and South-East Asia (WHO region) ranks 2nd of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.